Ray Therapeutics Pulls $125M From An All-Star Roster Of Investors
Ray Therapeutics closes an upsized $125M Series B to advance its optogenetic gene therapy for retinitis pigmentosa.
Category Highly Important
Jeff Jonas Raised $106M. Then Bought Programs From Eisai and Hansoh.
Tortugas Neuroscience launches with $106M and two in-licensed clinical-stage assets from Eisai and Hansoh.
Immunofoco Already Has a Phase 3 CAR-T. Now It’s Making Them Inside the Patient.
Immunofoco presented preclinical data for IMV102, an in vivo BCMA CAR-T built on its iMAGIC lentiviral platform.
EpiBiologics Is Taking Extracellular Protein Degradation Into The Clinic
EpiBiologics dosed the first patient with EPI-326, a bispecific antibody degrader hitting wild-type and mutant EGFR.
A 488-Amino-Acid CRISPR That Fits Inside an AAV
Metagenomi published a compact Cas12f CRISPR variant small enough for single-AAV delivery, with editing activity that rivals larger systems.
A Chinese Biotech Just Filed the World’s First LILRB4 T Cell Engager
Mabwell's 6MW5311 became the first LILRB4/CD3 bispecific T cell engager to reach clinical submission anywhere in the world.
67% in Ovarian. 50% in Prostate. Without the Bone Marrow Beating.
Acerand Therapeutics drops Phase I/II data for ACE-106, a PARP1-selective inhibitor with response rates that put it in best-in-class territory.
20 Minutes to Burn a Pancreatic Tumor
Sonire Therapeutics closes $18M Series A for focused ultrasound ablation in pancreatic cancer.
Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.
Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.
FDA Breakthrough for a Urine-Based Cancer Test
TOBY Inc receives FDA Breakthrough Device Designation for a urine-based multi-cancer early detection test.